Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | KLK7 | P49862 | 2/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | PTPRA | P18433 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549580 | 0.91 | PTPN1 (0.42) | TGM2PTPN1HTR2ACTSLP2RX7 | |
| SCHEMBL17161225 | 0.79 | HTR2A (0.44) | TGM2MAPTHTR2A | |
| SCHEMBL3726655 | 0.76 | TGM2 (0.46) | TGM2CTSLP2RX7 | |
| SCHEMBL30471718 | 0.76 | SSTR3 (0.50) | TGM2PTPN1HTR2ACTSL | |
| SCHEMBL13041082 | 0.76 | KLK7 (0.57) | TGM2KLK7KLK5MAPTITGB3 | |
| SCHEMBL18560008 | 0.76 | KLK7 (0.57) | TGM2KLK7KLK5MAPTITGB3 | |
| SCHEMBL16124224 | 0.74 | PPARG (0.47) | P4HBPTPN1MAPTHTR2AITGB3 | |
| SCHEMBL28538646 | 0.74 | PPARG (0.47) | P4HBPTPN1MAPTHTR2AITGB3 | |
| SCHEMBL7302025 | 0.73 | TGM2 (0.56) | TGM2KLK7KLK5MAPTITGB3 | |
| SCHEMBL28538964 | 0.72 | HTR2A (0.49) | TGM2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2026-04-21 | — | — | US | claimed |
| US-20240342304-A1 | Tetravalent Antibody-Drug Conjugates and Use Thereof | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-10-17 | — | — | US | claimed |
| US-11951173-B2 | Tetravalent antibody-drug conjugates and use thereof | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2024-04-09 | — | — | US | claimed |
| CN-116419929-B | Engineered EGFR antibodies with reduced affinity, drug conjugates and uses thereof | 百力司康生物医药(杭州)有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-20240075154-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-03-07 | — | — | US | claimed |
| US-20240009318-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-01-11 | — | — | US | claimed |
| US-20240002527-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2024-01-04 | — | — | US | claimed |
| US-20230414781-A1 | ANTI-CD276 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN) | 2023-12-28 | — | — | US | claimed |
| EP-4247425-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| EP-4247853-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| EP-4247855-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2023-09-27 | — | — | EP | claimed |
| CN-116528911-A | anti-CD 73 antibody, antibody-conjugated drug and application thereof | 百力司康生物医药(杭州)有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-116419929-A | Engineered EGFR antibodies with reduced affinity, drug conjugates and uses thereof | 百力司康生物医药(杭州)有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-116406382-A | anti-CD 276 antibody, antibody-conjugated drug and application thereof | 百力司康生物医药(杭州)有限公司 | 2023-07-07 | — | — | CN | claimed |
| WO-2022105881-A1 | ANTI-CD73 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105873-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022104692-A1 | ENGINEERED ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105879-A1 | ANTI-CD276 ANTIBODY, ANTIBODY-DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
| WO-2022105878-A1 | MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF | Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (CN) | 2022-05-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605457-B2 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | EGFR, ERBB2, IGSF11 | TGM2 790/4885P4HB 921/4885PSMB8 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.